Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

Glioblastoma is the most aggressive primary brain tumor in humans and is virtually incurable with conventional therapies. Chimeric antigen receptor (CAR) T cell therapy targeting the glioblastoma antigen EphA2 is an attractive approach to improve outcomes because EphA2 is expressed highly in gliobla...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Zhongzhen, Prinzing, Brooke L., Cao, Felicia, Gottschalk, Stephen, Krenciute, Giedre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852415/
https://www.ncbi.nlm.nih.gov/pubmed/29552579
http://dx.doi.org/10.1016/j.omtm.2018.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852415/
https://www.ncbi.nlm.nih.gov/pubmed/29552579
http://dx.doi.org/10.1016/j.omtm.2018.01.009

Ejemplares similares